Parabilis Medicines, a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering (IPO) of 33.5 million shares at $20 each, expected to raise approximately $670 million. Additionally, Parabilis agreed to a concurrent private placement of 4.17 million shares to Regeneron Pharmaceuticals at $18 per share, expected to bring in about $75 million. The IPO shares will begin trading on Nasdaq under the ticker PBLS on June 10, 2026, with the offering closing around June 11, subject to customary conditions. This capital raise supports Parabilis' development of novel medicines targeting difficult protein targets in human disease.
Halper Sadeh LLC is investigating whether shareholders of Nuvalent, SUNation Energy, Organon & Co., and Taylor Morrison Home Corporation are receiving fair treatment in their companies' recent sales or mergers. The law firm highlights potential confl...
Inno Holdings (INHD) stock was halted by Nasdaq after soaring over 3,600% in one session, rising from about $1.01 to above $66. The surge followed a $3 million contract with a Hong Kong AI firm, which is small compared to typical mid-cap expenses. Th...
Metamucil has introduced "Metamucil Mic Grab," a new digital content series hosted by registered dietitian Amy Shapiro, featuring 90s icons Lance Bass and Danielle Fishel. The series aims to educate viewers on the fibermaxxing trend, which encourages...
The U.S. military conducted retaliatory strikes against Iran following the downing of an American Apache helicopter. The strikes, described by U.S. Central Command as a proportional response to Iranian aggression, were announced on social media. Defe...
Entering XM partner code 274PQ during account registration in 2026 activates a 100% welcome bonus that doubles your first deposit's trading margin. This bonus provides a larger free margin buffer, allowing trades more room to recover from adverse mar...
